Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 18/20 | 0.60 |
| ▸ | TNF | P01375 | 2/20 | 0.42 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200971 | 0.85 | ADAM17 (0.72) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL10200967 | 0.84 | ADAM17 (0.71) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL7943649 | 0.81 | ADAM17 (0.74) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL10200976 | 0.81 | ADAM17 (0.76) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL10200961 | 0.79 | ADAM17 (0.72) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL7943117 | 0.78 | ADAM17 (0.65) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL10199384 | 0.77 | ADAM17 (0.79) | ADAM17TNF | |
| SCHEMBL7943251 | 0.77 | ADAM17 (0.83) | ADAM17TNF | |
| SCHEMBL7941661 | 0.77 | ADAM17 (0.72) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL10263357 | 0.77 | ADAM17 (0.69) | ADAM17TNFADAM10MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010054278-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |